Increased risk of prostate cancer

July 2011
Internal Medicine Alert;7/15/2011 Pharmacology Watch, p1
The article reports on the drug warning issued by the U.S. Food & Drug Administration (FDA) concerning an increased risk for prostate cancer in patients who are taking 5-alfa reductase inhibitors finasteride (Proscar, Propecia) and dutasteride (Avodart, Jalyn).


Related Articles

  • FDA warns of serious prostate cancer with 5-αRIs.  // Reactions Weekly;6/18/2011, Issue 1356, p3 

    The article focuses on a safety announcement issued by the U.S. Food and Drug Administration (FDA) has reported that 5-α reductase inhibitors may increase the risk of high-grade prostate cancer.

  • Increased risk of prostate cancer. Elliott, William T. // Neurology Alert;Aug2011 Pharmacology Watch, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) issued a warning that 5-alfa reductase inhibitors finasteride and dutasteride may increase the risk of prostate cancer. Data was gathered from studies which aimed to evaluate whether these drugs offer protection against...

  • Complementary and Alternative Medicine Patients Are Talking About: PC-SPES. Lee, Colleen O. // Clinical Journal of Oncology Nursing;Feb2005, Vol. 9 Issue 1, p113 

    Talks about the PC-SPES Chinese herbal supplement for prostate cancer. Withdrawal from the market after being recalled by the U.S. Food and Drug Administration; Indications of the supplement; Efficacy; Adverse reactions.

  • GnRH agonists' safety profile under FDA review for diabetes, CVD risks.  // Formulary;Jun2010, Vol. 45 Issue 6, p188 

    The article discusses the release of a U.S. Food and Drug Administration advisory which warns of an increased risk of developing cardiovascular disease (CVD), diabetes, stroke and sudden death among men being treated for prostate cancer with gonadotropin-releasing hormone (GnRH) agonists. GnRH...

  • NEWSLINE.  // Monthly Prescribing Reference;May2010, Vol. 26 Issue 5, pA8 

    The article offers news briefs related to the pharmaceutical industry in the U.S. Metered-dose inhalers (MDI) that will be removed from the market include the Alupent Inhaler, Azmacort and Maxair Autohaler. The Food and Drug Administration (FDA) is assessing the potential of Stalevo, a treatment...

  • Genetic Tests for Prostate Cancer. Kern, Adam; Partin, Alan W. // Reviews in Urology;2013, Vol. 15 Issue 4, p208 

    The article discusses three new genetic assays for prostate cancer which have been recently approved or seeking approval from the U.S. Food and Drug Administration (FDA).

  • Adverse drug event monitoring at the Food and Drug Administration. Ahmad, Syed Rizwanuddin // JGIM: Journal of General Internal Medicine;Jan2003, Vol. 18 Issue 1, p57 

    The Food and Drug Administration (FDA) is responsible not only for approving drugs but also for monitoring their safety after they reach the market. The complete adverse event profile of a drug is not known at the time of approval because of the small sample size, short duration, and limited...

  • Doctors, consumers and adverse reactions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Reports on the reports generated by medWatch, a new Food and Drug Administration (FDA) program to encourage doctors to voluntarily report adverse effects caused by drugs and devices. Effects defined as serious; Monitoring of drugs and devices after approval as the weakest link in FDA's oversight...

  • America's real drug problem.  // HealthFacts;Jun98, Vol. 23 Issue 6, p4 

    Reports on the increasing number of fatalities associated with prescription drugs in the United States. Emergence of adverse drug reactions (ADRs) as fourth leading cause of death in the U.S.; US Food & Drug Administration's (FDA) limited resources in monitoring drug safety; Reliance of FDA on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics